Roche Bid for Illumina (ILMN) Drives Biotech Sector to New Highs
M&A Theme Provides Underlying Bid to Market Roche Holding, the most diversified diagnostics and pharmaceutical Company with an aggressive leveraged strategy for the molecular basis of disease and personalized medicine has offered $5.7B for the leading Company in genetic sequencing and life...
“January Effect” Traders: Take Some Profits
If you followed our trades from November /December you made at least 20% so why push it? The Rayno Life Science Portfolio is down 0.75% today in a choppy market. Our mid-cap biopharmaceutical index is down 0.87% but diagnostics and tools are down only 0.3% as they were hit hard over the past...
“January Effect” Rolls On with Biotech Stocks Up Over 1%, 9.3% MTD
Seems a Bit Frothy Large and mid-cap biopharmaceutical stocks continued to surge today with the bellwether ETF IBB ($114) hitting one year highs of $114.15 today. Many of our recent focus picks also continue to roll ahead: Astex (ASTX $2.18) up 4.8%, Gilead (GILD $47.40) up 2.4%,ImmunoGen (IMGN...
Trends from the JPMorgan Healthcare Conference 2012
Healthcare: Broad Trends and Business Concepts for 2012 Last year we published an overview of trends for the 2011 JPMorgan Conference. Here is a very brief review from this year’s Conference: The lagging Life Science Tools sector was ignited by new sequencing and genetic analysis products...
“January Effect” Rally: A Cliched Trade That Really Works
You read about it every year, and always there are skeptics, but in Q4 2011 to Q 2012 the “January effect ” rally for small cap and life science stocks were big winners. Why does this happen? Not so important just that it does happen. Here are our December focus picks (see earlier...
